tegafur and Nasopharyngeal Neoplasms
tegafur has been researched along with Nasopharyngeal Neoplasms in 13 studies
Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)." | 7.96 | Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. ( Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020) |
"The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC)." | 7.91 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. ( Chao, TY; Chen, JH; Ho, CL; Huang, WY; Lee, JC, 2019) |
"The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)." | 3.96 | Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. ( Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020) |
"The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC)." | 3.91 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. ( Chao, TY; Chen, JH; Ho, CL; Huang, WY; Lee, JC, 2019) |
"Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
" Most adverse events were mild." | 1.40 | Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014) |
Research
Studies (13)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (30.77) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (23.08) | 29.6817 |
2010's | 5 (38.46) | 24.3611 |
2020's | 1 (7.69) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, JH | 1 |
Huang, WY | 1 |
Ho, CL | 1 |
Chao, TY | 1 |
Lee, JC | 1 |
Zong, J | 1 |
Xu, H | 1 |
Chen, B | 1 |
Guo, Q | 1 |
Xu, Y | 1 |
Chen, C | 1 |
Weng, Y | 1 |
Zheng, W | 1 |
Pan, J | 1 |
Lin, S | 1 |
Zhou, L | 1 |
Lin, J | 1 |
Wu, G | 1 |
Chen, J | 1 |
Huang, X | 1 |
Zhang, S | 1 |
Lv, T | 1 |
Wang, Y | 1 |
Ou, D | 1 |
Liu, P | 1 |
Qin, S | 1 |
Liu, L | 1 |
Lou, P | 1 |
Wang, X | 1 |
Twu, CW | 1 |
Wang, WY | 1 |
Chen, CC | 1 |
Liang, KL | 1 |
Jiang, RS | 1 |
Wu, CT | 1 |
Shih, YT | 1 |
Lin, PJ | 1 |
Liu, YC | 1 |
Lin, JC | 1 |
Peng, PJ | 1 |
Cheng, H | 1 |
Ou, XQ | 1 |
Zeng, LJ | 1 |
Wu, X | 1 |
Liu, YM | 1 |
Lin, Z | 1 |
Tang, YN | 1 |
Wang, SY | 1 |
Zhang, HY | 1 |
Chen, ZB | 1 |
Okita, J | 1 |
Hatta, C | 1 |
Terada, T | 1 |
Saeki, N | 1 |
Ogasawara, H | 1 |
Kakibuchi, M | 1 |
Kamikonya, N | 1 |
Sakagami, M | 1 |
Kwong, DL | 1 |
Sham, JS | 1 |
Au, GK | 1 |
Chua, DT | 1 |
Kwong, PW | 1 |
Cheng, AC | 1 |
Wu, PM | 1 |
Law, MW | 1 |
Kwok, CC | 1 |
Yau, CC | 1 |
Wan, KY | 1 |
Chan, RT | 1 |
Choy, DD | 1 |
Park, JH | 1 |
Nam, SY | 1 |
Lee, SW | 1 |
Kim, SB | 1 |
Kim, SY | 1 |
Lee, BJ | 1 |
Cho, KJ | 1 |
Kim, JH | 1 |
Ahn, SD | 1 |
Shin, SS | 1 |
Choi, SH | 1 |
Ahn, JH | 1 |
Choi, EK | 1 |
Inuyama, Y | 1 |
Horiuchi, M | 1 |
Kohno, N | 1 |
Mashino, S | 1 |
Ozu, R | 1 |
Asaoka, K | 1 |
Tsujii, H | 1 |
Kamada, T | 1 |
Tsuji, H | 1 |
Takamura, A | 1 |
Matsuoka, Y | 1 |
Usubuchi, H | 1 |
Irie, G | 1 |
Furukawa, M | 2 |
Ohoka, H | 2 |
Sakashita, H | 1 |
Umeda, R | 2 |
Kamide, M | 1 |
Clinical Trials (3)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
3 trials available for tegafur and Nasopharyngeal Neoplasms
Article | Year |
---|---|
IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplati | 2019 |
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Other Studies
10 other studies available for tegafur and Nasopharyngeal Neoplasms
Article | Year |
---|---|
Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma.
Topics: Administration, Metronomic; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Chemoradio | 2019 |
Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Chemoradiotherapy; Drug Combinations; Female; Humans; Maintenance Chemother | 2019 |
Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Car | 2020 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem | 2014 |
Concurrent chemo-radiotherapy for nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car | 2004 |
Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 1989 |
Synergistic antitumor activity of cisplatin and UFT in nude mice bearing transplantable nasopharyngeal hybridoma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration S | 1989 |
[Combination chemotherapy with cisplatin and UFT malignant tumors of the head and neck--experimental study of human nasopharyngeal carcinoma (A2L/AH) xenografted to nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admin | 1988 |